Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing.

Slides:

Advertisements

Similar presentations

Figure 2. The graphic integration of CNAs with altered expression genes in lung AD and SCC. The red lines represent the amplification regions for CNA and.

Advertisements

From: Introducing the PRIDE Archive RESTful web services

Figure 1. (A) The VEGF promoter PQS and scheme of G oxidation to OG, as well as (B) the proposed APE1-dependent pathway ... Figure 1. (A) The VEGF promoter.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. A novel image analysis tool to monitor epigenetic changes in spatiotemporal distribution of chromatin in live ... Figure 1. A novel image analysis.

Figure 1. Overview of the workflow of NetworkAnalyst 3.0.

Figure 1 The study area within Vienna Zoo is outlined in red

Figure 7. Primary cells from prostate tumours are more sensitive to ML than adjacent non-cancerous cells from the ... Figure 7. Primary cells from.

Figure 1. AML containing the t(8:21) are extremely sensitive to CDK inhibitors. (A–C) Alamar blue assays were used to ... Figure 1. AML containing the.

Figure 1. Effect of random T/A→dU/A substitutions on transcription by T7 RNAP using a 321 bp DNA transcription template ... Figure 1. Effect of random.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

Figure 1. Position and number of NLS improves genome editing by AsCas12a, LbCas12a and FnoCas12a. (A) General schematic ... Figure 1. Position and number.

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

Figure 2. Ectopic expression of PLZF modulates H3K27ac at enhancer regions in myeloid cells. (A) Box plots showing ... Figure 2. Ectopic expression of.

Figure 1. BRCA1-associated R-Loop accumulation at a non-coding region upstream of ESR1 locus. (A) Alignment of DRIP-seq ... Figure 1. BRCA1-associated.

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

Figure 1. Designing a cell-specific Cas-ON switch based on miRNA-regulated anti-CRISPR genes. (A) Schematic of the ... Figure 1. Designing a cell-specific.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

Figure 1. Schematic illustration of CSN and NDM construction and our statistic model. (A) CSN and NDM construction. (i) ... Figure 1. Schematic illustration.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Figure 1. autoMLST workflow depicting placement and de novo mode

Figure 1. The 12 species in this study and details of the improved G4-seq method. (A) Phylogenetic representation of ... Figure 1. The 12 species in this.

Figure 1. Comparison of weighted estimates of diarrhoea prevalence in children under five by country between PMA Figure 1. Comparison of weighted.

Figure 1. Nanopore methylation calls are consistent with expected results and established technologies. (A) Metaplot of ... Figure 1. Nanopore methylation.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Figure 1. Chemical structures of DNA and tc-DNA

Fig. 1 Mean change from baseline in ANC ± s. e

Point estimates with ... Point estimates with 95% CI. HR: hip replacement; KR: knee replacement. Unless provided in the caption above, the following copyright.

FIGURE 1 Participant flow diagram. Exercise Counseling Clinic (ECC).

Graph 1. The number of homicide cases per year discussing neuro-evidence. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Analysis of human TRIM5α protein with Blast-Search and PhyML+SMS ‘One click’ workflow. (A) NGPhylogeny.fr ... Figure 1. Analysis of human TRIM5α.

Figure 1. Mean concentration–time profiles of ascending doses of ivermectin in (a) PSAC and (b) SAC. Weight-dependent ... Figure 1. Mean concentration–time.

Figure 1 Nelson-Aalen estimates of the cumulative incidence rates for patients on versus off IST. ON = optic neuritis; ... Figure 1 Nelson-Aalen estimates.

FIGURE 1 Malta: a plate-style food guide

Figure 1. A, Crude incidence rates per 100 person-years of follow-up and 95% confidence intervals for each solid organ ... Figure 1. A, Crude incidence.

FIGURE 1 Study consort diagram

Figure 1. Illustration of DGR systems and their prediction using myDGR

Figure 1. The pipeline of Aggrescan3D 2.0 server.

Figure 1. Summary of experimental conditions and data normalization

Figure 1. The workflow of Cistrome-GO

Figure 1. Prediction result for birch pollen allergen Bet v 1 (PDB: 1bv1), as obtained by comparison to the cherry ... Figure 1. Prediction result for.

Figure 1. Using Voronoi tessellation to define contacts

Figure 1. Designed cotranscriptional RNA structures

Fig. 1. iS-CellR pipeline overview

Figure 4. RLS spectra of (A) TMPipEOPP and (B) OMHEPzEOPP in the presence of different concentrations of KRAS. The RLS ... Figure 4. RLS spectra of (A)

Figure 1. PaintOmics 3 workflow diagram

Figure 1. Schematic diagram of solar energy and coal-fired power generation system. Unless provided in the caption above, the following copyright applies.

Figure 1. Uncertainty reduction, value creation, and appropriation in two case studies. Unless provided in the caption above, the following copyright applies.

Figure 1 Ratio of the geometric mean concentration of hsTnT (A) and sST2 (B) at baseline (BL) and each subsequent ... Figure 1 Ratio of the geometric mean.

Figure 1. The configuration menu allows the user to choose among the main visualization/processing options of the ... Figure 1. The configuration menu.

Figure 1. ULS1 deletion causes sensitivity to ACF due Top2 activity

Figure 1. (A) Architecture of Doc2Hpo. (B) Interactive user interface

Figure 1. MERMAID web server interface (Start page, Parameter page): MERMAID provides two ways to submit a protein ... Figure 1. MERMAID web server interface.

Figure 1. Yvis platform overview

Figure 1. The framework of NetGO with seven steps

Figure 1. Workflow of the HawkDock server that is divided into three major steps: (i) input of unbound or bound protein ... Figure 1. Workflow of the HawkDock.

Figure 1. Overview of features that can be assessed in a single RegulationSpotter VCF analysis run. Depending upon a ... Figure 1. Overview of features.

Figure 1 Distribution of WCD use days in WEARIT-II

Figure 1. SQL schema used by RetroRules

Figure 1. Scheme of a phosphorothioated-terminal hairpin formation and self-priming extension (PS-THSP) for selection ... Figure 1. Scheme of a phosphorothioated-terminal.

Figure 1 Correlation between en face Oil-Red O staining and aortic root lesion size vs. plasma cholesterol and ... Figure 1 Correlation between en face.

Figure 1. Excess cost of methicillin-resistant Staphylococcus aureus (MRSA) compared with methicillin-susceptible S. ... Figure 1. Excess cost of methicillin-resistant.

Figure 1 Genetic results. No case had more than one diagnostic result

Figure 1. Prevalence of parasitic infection and anemia among the children. Unless provided in the caption above, the following copyright applies to the.

Figure 1. Optimization of the variant calling algorithm, ADIScan1, by tangential conversion of read depth ratios ... Figure 1. Optimization of the variant.

Figure 1. GWAS Catalog associations for coronary artery disease plotted across all chromosomes. Associations added ... Figure 1. GWAS Catalog associations.

Source:Zimnisky (2014). Source:Zimnisky (2014).

Figure 1 Mechanisms of mitral regurgitation.

Fig. 1. Examples of plots of NanoPlot and NanoComp

Figure 1. (A) Overview of ENPD including data source, data processing and features. Transcriptomes from TSA, genomes ... Figure 1. (A) Overview of ENPD.

Presentation transcript:

Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks ... Figure 4. (A) Venn diagram showing the overlap of peaks differentially changed in DHT as compared to NT with peaks changed by DHT and ARE-1 as compared to NT. (B and C) Density analysis of overlapping peaks with <1.5 absolute fold change between DHT/NT and DHT+ARE-1/NT (B) and peaks with >2-fold change when comparing DHT/NT to DHT+ARE-1/NT (C). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz153, https://doi.org/10.1093/nar/gkz153 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3. (A) Illustration of match and mismatch ARE-1 binding sites Figure 3. (A) Illustration of match and mismatch ARE-1 binding sites. Mismatches are shown in red and boxed. (B) ... Figure 3. (A) Illustration of match and mismatch ARE-1 binding sites. Mismatches are shown in red and boxed. (B) Melting temperature analysis of match and mismatch sequences shown in A. C + D) Motif density analysis of possible ARE half sites in peaks unique to DHT/NT (C) and overlapping between DHT/NT and DHT/DHT + ARE-1 (D). Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz153, https://doi.org/10.1093/nar/gkz153 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2. ChIP-seq analysis of the KLK3 promoter ARE I (A) and PMEPA1 (B). (C) Overlap of peaks differentially changed ... Figure 2. ChIP-seq analysis of the KLK3 promoter ARE I (A) and PMEPA1 (B). (C) Overlap of peaks differentially changed in DHT relative to NT, and peaks changed in DHT relative to DHT and ARE-1. (D) Identified peaks were annotated by genomic region by ChIPseeker. (E) Top ARE motif found by MEME in the indicated peak sets. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz153, https://doi.org/10.1093/nar/gkz153 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 1. (A) Structure of Py-Im polyamide ARE-1 Figure 1. (A) Structure of Py-Im polyamide ARE-1. (B) Nuclear localization of ARE-1-FITC in LNCaP-95 cells after 16-h ... Figure 1. (A) Structure of Py-Im polyamide ARE-1. (B) Nuclear localization of ARE-1-FITC in LNCaP-95 cells after 16-h treatment. (C) Cell viability as determined by CellTiterGlo assay after 72-h treatment. IC<sub>50</sub> is indicated in parentheses. (D) Relative expression of KLK3 in LNCaP-95 cells after the indicated treatments. Cells were co-treated with ARE-1, enzalutamide, or pyrvinium pamoate and DHT at the indicated concentrations and RNA harvested at 24 h. (E) Schedule of LNCaP-95 xenograft experiment. Animals were engrafted, allowed to grow tumors, castrated, allowed to recover for 7–10 days and then treated with ARE-1 or vehicle at indicated times. (F) Tumor volumes of LNCaP-95 xenografts in castrated mice treated with vehicle or 2.5 mg/kg ARE-1 as shown in E. N = 11 for both groups; * P < 0.05, ** P < 0.01, **** P < 0.0001. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Res, gkz153, https://doi.org/10.1093/nar/gkz153 The content of this slide may be subject to copyright: please see the slide notes for details.